FilingSEC EDGAR8-K
Tectonic Therapeutic Reports Q3 2026 Financial Results and Clinical Pipeline Progress
· SEC accepted
StageClinical Stage
Filing content
Tectonic Therapeutic announced its Q3 2026 financial results, reporting positive Phase 1a results for TX2100 and the first patient dosing in the Phase 2a trial for TX45.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…